Bausch Health Companies Inc (TO:BHC) — Market Cap & Net Worth
Market Cap & Net Worth: Bausch Health Companies Inc (BHC)
Bausch Health Companies Inc (TO:BHC) has a market capitalization of $2.13 Billion (CA$2.95 Billion) as of September 16, 2026. Listed on the TO stock exchange, this Canada-based company holds position #5925 globally and #193 in its home market, demonstrating a -13.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bausch Health Companies Inc's stock price CA$7.88 by its total outstanding shares 373990561 (373.99 Million). Also see BHC current and non-current assets for a full breakdown of the balance sheet.
Bausch Health Companies Inc Market Cap History: 2015 to 2026
Bausch Health Companies Inc's market capitalization history from 2015 to 2026. Data shows change from $38.03 Billion to $2.13 Billion (-26.07% CAGR). Also see BHC cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Bausch Health Companies Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P TSX Composite Index (Canada)
GSPTSE
|
$3.86 Trillion | 0.06% | #158 of 225 |
Weight: Bausch Health Companies Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bausch Health Companies Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bausch Health Companies Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Bausch Health Companies Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.25x
Bausch Health Companies Inc's market cap is 0.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
16.14x
Bausch Health Companies Inc's market cap is 16.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $5.27 Billion | $9.67 Billion | -$2.41 Billion | 0.54x | N/A |
| 2017 | $7.09 Billion | $8.72 Billion | $2.40 Billion | 0.81x | 2.95x |
| 2018 | $6.83 Billion | $8.38 Billion | -$4.15 Billion | 0.82x | N/A |
| 2019 | $10.52 Billion | $8.60 Billion | -$1.78 Billion | 1.22x | N/A |
| 2020 | $7.14 Billion | $8.03 Billion | -$559.00 Million | 0.89x | N/A |
| 2021 | $9.45 Billion | $8.43 Billion | -$937.00 Million | 1.12x | N/A |
| 2022 | $2.30 Billion | $8.12 Billion | -$212.00 Million | 0.28x | N/A |
| 2023 | $2.88 Billion | $8.76 Billion | -$592.00 Million | 0.33x | N/A |
| 2024 | $3.14 Billion | $9.62 Billion | -$46.00 Million | 0.33x | N/A |
| 2025 | $2.58 Billion | $10.45 Billion | $159.75 Million | 0.25x | 16.14x |
Competitor Companies of BHC by Market Capitalization
Companies near Bausch Health Companies Inc in the global market cap rankings as of September 16, 2026. Review Bausch Health Companies Inc (BHC) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Bausch Health Companies Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Bausch Health Companies Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Bausch Health Companies Inc's market cap moved from $38.03 Billion to $ 2.13 Billion, with a yearly change of -26.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$2.13 Billion | -17.31% |
| 2025 | CA$2.58 Billion | -17.99% |
| 2024 | CA$3.14 Billion | +9.31% |
| 2023 | CA$2.88 Billion | +25.06% |
| 2022 | CA$2.30 Billion | -75.67% |
| 2021 | CA$9.45 Billion | +32.30% |
| 2020 | CA$7.14 Billion | -32.06% |
| 2019 | CA$10.52 Billion | +53.94% |
| 2018 | CA$6.83 Billion | -3.63% |
| 2017 | CA$7.09 Billion | +34.57% |
| 2016 | CA$5.27 Billion | -86.15% |
| 2015 | CA$38.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Bausch Health Companies Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.13 Billion USD |
| MoneyControl | $2.13 Billion USD |
| MarketWatch | $2.13 Billion USD |
| marketcap.company | $2.13 Billion USD |
| Reuters | $2.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmac… Read more